--- title: "Fate Therap | 8-K: FY2026 Q2 Revenue Beats Estimate at USD 2.082 M" type: "News" locale: "en" url: "https://longbridge.com/en/news/295799923.md" datetime: "2026-08-13T12:37:07.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/295799923.md) - [en](https://longbridge.com/en/news/295799923.md) - [zh-HK](https://longbridge.com/zh-HK/news/295799923.md) --- # Fate Therap | 8-K: FY2026 Q2 Revenue Beats Estimate at USD 2.082 M Revenue: As of FY2026 Q2, the actual value is USD 2.082 M, beating the estimate of USD 1.274 M. EPS: As of FY2026 Q2, the actual value is USD -0.25, beating the estimate of USD -0.2682. EBIT: As of FY2026 Q2, the actual value is USD -31.13 M. ### Cash & Investment Position As of June 30, 2026, Fate Therapeutics, Inc. reported total cash, cash equivalents, and investments of $153.8 million, which represents a quarterly decrease of $21 million. Cash and cash equivalents were $32,429 thousand, and short-term investments amounted to $121,341 thousand on this date. This is a decrease from December 31, 2025, when cash and cash equivalents were $46,628 thousand and short-term investments were $157,029 thousand. Total current assets as of June 30, 2026, were $157,953 thousand, a reduction from $208,704 thousand as of December 31, 2025. ### Collaboration Revenue Collaboration revenue for the second quarter of 2026 increased to $2,082 thousand from $1,907 thousand in the second quarter of 2025. For the six months ended June 30, 2026, collaboration revenue was $3,381 thousand, a decrease from $3,536 thousand for the same period in 2025. This revenue was derived from preclinical development activities under the company’s collaboration with Ono Pharmaceutical. ### Total Operating Expenses Total operating expenses for the second quarter of 2026 were $33,216 thousand, a reduction from $38,875 thousand in the second quarter of 2025. This included research and development (R&D) expenses of $24,387 thousand and general and administrative (G&A) expenses of $8,829 thousand. For the six months ended June 30, 2026, total operating expenses decreased by $14.3 million to $67,515 thousand, compared to $81,784 thousand for the same period in 2025. R&D expenses for the six-month period decreased by $7.5 million (13%) to $49,090 thousand, and G&A expenses decreased by $6.8 million (27%) to $18,425 thousand compared to the prior year. Non-cash stock-based compensation expense for the second quarter of 2026 was $3.5 million. ### Loss from Operations Loss from operations for the second quarter of 2026 was - $31,134 thousand, an improvement from - $36,968 thousand for the second quarter of 2025. For the six months ended June 30, 2026, the loss from operations was - $64,134 thousand, an improvement compared to - $78,248 thousand for the same period in 2025. ### Other Income (Expense), Net Interest income for the second quarter of 2026 was $1,555 thousand, down from $2,921 thousand in the second quarter of 2025. The change in fair value of stock price appreciation milestones was - $580 thousand in Q2 2026, compared to - $73 thousand in Q2 2025. Total other income, net, for Q2 2026 was $975 thousand, decreasing from $2,898 thousand in Q2 2025. For the six months ended June 30, 2026, interest income was $3,422 thousand, and the change in fair value of stock price appreciation milestones was - $660 thousand, resulting in total other income, net, of $2,762 thousand for the period. ### Net Loss Net loss for the second quarter of 2026 was - $30,159 thousand, or - $0.25 per share, an improvement from - $34,070 thousand, or - $0.29 per share, for the second quarter of 2025. For the six months ended June 30, 2026, net loss was - $61,372 thousand, or - $0.51 per share, compared to - $71,691 thousand, or - $0.61 per share, for the same period in 2025. ### Comprehensive Loss Comprehensive loss for the second quarter of 2026 was - $30,199 thousand, compared to - $34,199 thousand for the second quarter of 2025. For the six months ended June 30, 2026, comprehensive loss was - $61,605 thousand, compared to - $71,897 thousand for the same period in 2025. This includes an unrealized loss on available-for-sale securities, net, of - $40 thousand in Q2 2026 and - $233 thousand year-to-date 2026. ### Shares Outstanding As of June 30, 2026, Fate Therapeutics, Inc. had 116.7 million common shares outstanding, 3.9 million pre-funded warrants outstanding, and 2.8 million preferred shares outstanding. Each preferred share is convertible into five common shares. ### Outlook / Guidance Fate Therapeutics, Inc. anticipates its operating runway will extend into 2028, supported by enhancements to the organization’s expense structure and its $153.8 million in cash, cash equivalents, and investments as of June 30, 2026. The company plans to complete enrollment for the RECLAIM-LN trial in the first half of 2028. Additionally, Fate Therapeutics, Inc. expects to provide the next clinical update on FT836 in the first half of 2027. ### Related Stocks - [FATE.US](https://longbridge.com/en/quote/FATE.US.md) ## Related News & Research - [Wedbush Reaffirms "Outperform" Rating for Fate Therapeutics (NASDAQ:FATE)](https://longbridge.com/en/news/295940831.md) - [Dimensional Fund Advisors LP Lowers Stock Holdings in Fate Therapeutics, Inc. $FATE](https://longbridge.com/en/news/295994710.md) - [Fate Therapeutics starts potentially registrational Phase 2 RECLAIM-LN trial of FT819 in lupus nephritis](https://longbridge.com/en/news/295923904.md) - [Fate Therapeutics wins FDA IND clearance for dual-target CAR-T candidate FT839](https://longbridge.com/en/news/292199195.md) - [Fate Therapeutics reports preliminary FT819 CAR-T data showing skin score improvement in systemic sclerosis patients](https://longbridge.com/en/news/291803727.md)